(3) track the date you first use each vial using a marker on the container
Shellsea Portillo Canales, an endocrinology fellow at SSM Health St
[DOI] [PubMed] [Google Scholar] 59
TERLIVAZ is currently the only approved pharmacologic treatment within the broader Acute Kidney Injury (AKI) landscape, having received FDA approval in September 2022 for hepatorenal syndrome-associated AKI (HRS-AKI), a high-mortality yet comparatively niche segment of AKI
Jing F, Zou Q, Wang Y, Cai Z, Tang Y (2021) Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation
Efficacy and safety of a new triple-combination agent for the treatment of facial melasma